Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | ACP3 | P15309 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 3/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | PRCP | P42785 | 3/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29793145 | 1.00 | HTR2A (0.54) | HTR2ARETACP3IDO1PDPK1 | |
| SCHEMBL7124003 | 0.84 | ACP3 (0.47) | HTR2ARETACP3IDO1PDPK1 | |
| SCHEMBL20536825 | 0.83 | HTR2A (0.61) | HTR2A | |
| SCHEMBL10903646 | 0.83 | ALOX12 (0.47) | HTR2ARETACP3PRCP | |
| SCHEMBL30094172 | 0.82 | IDO1 (0.50) | HTR2ARETIDO1PDPK1CYP11B2 | |
| SCHEMBL1117278 | 0.82 | IDO1 (0.50) | HTR2ARETIDO1PDPK1CYP11B2 | |
| SCHEMBL10862776 | 0.82 | TDP1 (0.46) | HTR2ARETACP3 | |
| SCHEMBL10905385 | 0.82 | HTR2A (0.49) | HTR2ARETACP3 | |
| SCHEMBL11549403 | 0.82 | HTR2A (0.40) | HTR2ARETACP3IDO1PDPK1 | |
| SCHEMBL30171215 | 0.81 | HTR2A (0.58) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2110380-B1 | Alpha-N-methylation of amino acids | HOFFMANN LA ROCHE (CH) | 2010-11-10 | — | — | EP | claimed |
| EP-2110380-A1 | Alpha-N-methylation of amino acids | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-21 | — | — | EP | claimed |
| US-20240182463-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2024-06-06 | — | — | US | disclosed |
| US-20240010627-A1 | NOVEL GUANIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME | PEPTIDREAM INC. (JP) | 2024-01-11 | — | — | US | disclosed |
| US-20240010627-A1 | NOVEL GUANIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME | PEPTIDREAM INC. (JP) | 2024-01-11 | — | — | US | disclosed |
| US-20240010627-A1 | NOVEL GUANIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME | PEPTIDREAM INC. (JP) | 2024-01-11 | — | — | US | disclosed |
| EP-4276096-A1 | NOVEL GUANIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME | PeptiDream Inc. (JP) | 2023-11-15 | — | — | EP | disclosed |
| WO-2022149610-A1 | NOVEL GUANIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME | ペプチドリーム株式会社 | 2022-07-14 | — | — | WO | disclosed |
| US-20200339565-A1 | PRODRUG SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2020-10-29 | — | — | US | disclosed |
| US-20190248785-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2019-08-15 | — | — | US | disclosed |
| US-10202379-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | SHIONOGI & CO., LTD. (JP) | 2019-02-12 | — | — | US | disclosed |
| EP-0010398-B1 | ISATIN DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-04-27 | — | — | EP | disclosed |
| EP-0056617-A2 | Cycloheptene derivatives, process and intermediates for their preparation, and pharmceuticals containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-07-28 | — | — | EP | disclosed |
| US-4243808-A | ANTIDEPRESSANTS; CENTRAL NERVOUS SYSTEM ACTIVITY | JOHN WYETH & BROTHER LIMITED (GB) | 1981-01-06 | — | — | US | disclosed |
| EP-0010398-A1 | Isatin derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-04-30 | — | — | EP | disclosed |
| US-4180670-A | Amino pyridine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1979-12-25 | — | — | US | disclosed |
| US-4048223-A | 3-Dimethylsulfamoyl-5-[amino(alkyl or alkylidene)]-5H-dibenzo [a,d]cycloheptenes | MERCK & CO., INC. (US) | 1977-09-13 | — | — | US | disclosed |
| US-3981917-A | Chemical compounds | MERCK & CO., INC. (US) | 1976-09-21 | — | — | US | disclosed |
| US-3978121-A | 5H Dibenzo[a,d]cycloheptene derivatives | MERCK & CO., INC. (US) | 1976-08-31 | — | — | US | disclosed |
| US-3965181-A | Tricyclic pharmacological agents, intermediates and methods of making | SYNTEX (U.S.A.) INC. (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182463-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | HTR2A 3244/4885RET 2798/4885ACP3 773/4885 |
| US-20190248785-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | HTR2A 3244/4885RET 2798/4885ACP3 773/4885 |
| US-20200339565-A1 | PRODRUG SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | PREP, UNG, DPP4 | HTR2A 3231/4885RET 2683/4885ACP3 782/4885 |
| US-10202379-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | PREP, UNG, DPP4 | HTR2A 3244/4885RET 2798/4885ACP3 773/4885 |
| US-20240010627-A1 | NOVEL GUANIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME | GMPS, MAPT, UROD | HTR2A 2165/4885RET 1037/4885ACP3 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.